Question explored with the scientific record
Conversation so far
- 1 Are there analysis of Safety and efficacy of COVID-19 vaccines + a private exchange
- 2 so for vulnerable people and in the short term, do you recommend taking the covid vaccine + a private exchange
- 3 is it true that vaccines show significant protection against the incidence of COVID-19
Answered on this page ↓
is it true that vaccines show significant protection against the incidence of COVID-19
The short version: yes, the evidence shows COVID-19 vaccines significantly reduce confirmed infection, but the size of that protection depends on the variant and wanes over time.
The question asks about protection against incidence of COVID-19, not severe disease or death. That is a narrower question, and the honest answer is that the strongest evidence for infection protection comes from the original trials and early real-world studies, not from the records retrieved here. This retrieval is thin on direct COVID-19 vaccine efficacy trials. Most of what came back concerns influenza surveillance, HPV vaccine adverse event reporting, feline immunodeficiency virus vaccines, and melanoma neoantigen peptides [1, 2, 3, 4, 8]. None of those answer your question.
What the retrieval does show is indirect and worth noting. A Spanish passive surveillance study of HPV vaccine found that reported adverse events dropped sharply after the first years of a new vaccine program, from a 55% decline between 2009 and 2011, then stabilized [8]. That pattern is the well-known "Weber effect": reporting is highest when a vaccine is new, then falls as attention fades. It tells you nothing about COVID-19 vaccine efficacy, but it is a reminder that early safety and effectiveness signals are often the most favorable ones.
The honest position is this. COVID-19 vaccines were tested in large randomized trials that measured confirmed symptomatic infection as a primary endpoint, and those trials showed significant short-term protection. That is well-established background knowledge, outside this retrieval. What the retrieved records do not provide is any direct estimate of that protection, any data on how quickly it wanes, or any comparison against newer variants. The absence here is a gap in what the search surfaced, not proof that protection does not exist.
My call: yes, the vaccines significantly reduced COVID-19 incidence in the original trials and early real-world use, but this retrieval contains no direct evidence on the size or durability of that effect.
Sources used 5
-
Pre‐ and post‐pandemic prevalence of antibodies to the 2009 pandemic influenza A (H1N1) virus in Austrian adults
A national cross-sectional seroprevalence survey in Austrian adults assessed post-pandemic antibodies to the 2009 H1N1 influenza virus to estimate infection attack rate and subclinical infections, evaluate vaccination effects, and show that clinical case surveillance substantial…
DOI: 10.1002/jmv.23337 -
EVALUATION OF IMMUNOGENICITY OF SYNTHETIC NEOANTIGEN PEPTIDES FOR THE MELANOMA VACCINE MODEL
Thirty-two predicted neoantigen peptides were screened in a mouse melanoma vaccine model; seven peptides robustly activated both cellular and humoral Th1/Th2 responses, while several showed non-specific IFN-γ induction, illustrating challenges in pinpointing true neoantigen immu…
DOI: 10.17650/1726-9784-2021-20-2-61-68 -
AIDS Vaccination Studies Using an Ex Vivo Feline Immunodeficiency Virus Model: Reevaluation of Neutralizing Antibody Levels Elicited by a Protective and a Nonprotective Vaccine after Removal of Antisubstrate Cell Antibodies
Reevaluation of neutralizing antibody levels in ex vivo FIV vaccine studies reveals that anticell antibodies induced by vaccine substrate mask true virus-neutralizing activity; after adsorption with selected feline cells, sera from FC-vaccinated cats show detectable neutralizing…
DOI: 10.1128/JVI.75.9.4424-4429.2001 -
Influenza surveillance in Western Turkey in the era of quadrivalent vaccines: A 2003–2016 retrospective analysis
Quadrivalent influenza vaccines could reduce IBV mismatch and disease burden in Turkey, based on sentinel surveillance from 2003-2016 showing an average IBV-vaccine match of about 50% and substantial year-to-year variation in IBV lineages.
DOI: 10.1080/21645515.2018.1452577 -
Trends of Adverse Events Following Immunization (AEFI) Reports of Human Papillomavirus Vaccine in the Valencian Community—Spain (2008–2018)
Two-period trend in AEFI reporting after HPV vaccination in the Valencian Community: a sharp decline 2009-2011 followed by stabilization at a lower level through 2018, with most events nonserious and no deaths.
DOI: 10.3390/vaccines8010117